Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Breast 2Tumor-Agnostic 1Lymphoid 1Gynecologic 1Genitourinary 1

Conditions

Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Breast Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 87Specimen Handling 76pembrolizumab 74enzalutamide 57Radiosurgery 57Radiotherapy 51Docetaxel 50Androgen Antagonists 48Gemcitabine 43Nivolumab 40darolutamide 39Prednisone 35Abiraterone Acetate 33enfortumab vedotin 32Biopsy 31Cisplatin 30Carboplatin 29apalutamide 28Standard of Care 28cabozantinib 27Pluvicto 27abiraterone 26Blood Specimen Collection 25Radiation 23Leuprolide 23Ipilimumab 23X-Rays 18relugolix 17Triptorelin Pamoate 17Surveys and Questionnaires 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × CX 5461 × Genitourinary × Clear all
NCT04890613 2026-04-28

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Senhwa Biosciences, Inc.

Phase 1 Recruiting
52 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡